Lindemann, K <br/><br/>
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  08 2016 
 - 1505-10 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdw238  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab--therapeutic use<br/>CA-125 Antigen--genetics<br/>Disease Progression<br/>Disease-Free Survival<br/>Doxorubicin--therapeutic use<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Platinum--therapeutic use<br/>Prognosis<br/>Response Evaluation Criteria in Solid Tumors